Lilly(US:LLY) GLP1减重宝典·2025-07-21 12:01Core Viewpoint - The article highlights the effectiveness and safety of GLP-1 receptor agonists, specifically Semaglutide and Tirzepatide, in treating obesity and improving health outcomes, as endorsed by public figures like Elon Musk [1][3][5]. Group 1: Efficacy of Semaglutide - Semaglutide has shown significant weight loss results in clinical trials, with an average weight reduction of 15% in obese patients, compared to only 2.4% in the placebo group [7][10]. - In the STEP 1 trial, 34% of participants lost over 20% of their body weight, while the average weight loss was 14.9% [7]. - The STEP 2 trial indicated a 10.6% average weight loss in type 2 diabetes patients, with improvements in cardiovascular risk factors and quality of life [8]. - The STEP 4 trial demonstrated that continuous use of Semaglutide led to an 18.2% weight reduction over time [9]. - Overall, Semaglutide has been approved by the FDA for long-term obesity management, marking it as a significant advancement in obesity treatment [10]. Group 2: Efficacy of Tirzepatide - Tirzepatide has shown promising results in the SURMOUNT trials, with weight reductions of 15.4% to 22.9% depending on the dosage, significantly outperforming the placebo group [11][12]. - The SURMOUNT-3 trial reported a weight loss of up to 26.6% after 12 weeks of lifestyle intervention combined with Tirzepatide treatment [13]. - In head-to-head trials, Tirzepatide demonstrated superior weight loss compared to Semaglutide, with an average reduction of 22.8 kg [13]. Group 3: Safety Profile - Semaglutide is generally well-tolerated, but gastrointestinal side effects such as nausea (17%), diarrhea (12.2%), and vomiting (6.4%) are common [15]. - Approximately 80% of Tirzepatide users reported at least one side effect, primarily gastrointestinal, with nausea reported in 33% of high-dose users [17]. - Experts suggest that Tirzepatide may have a lower frequency and milder symptoms of side effects compared to Semaglutide due to its dual action mechanism [19].